Skip to main content

Aptose Biosciences Inc.

corporate_fare Company Profile

Aptose Biosciences Inc.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Exchange: OTCSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed APTOF - Latest Insights

APTOF
Mar 31, 2026, 5:29 PM EDT
Filing Type: 10-K
Importance Score:
9
APTOF
Mar 31, 2026, 5:23 PM EDT
Filing Type: 8-K
Importance Score:
9
APTOF
Mar 31, 2026, 4:59 PM EDT
Filing Type: 8-K
Importance Score:
8
APTOF
Mar 23, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
APTOF
Mar 19, 2026, 7:40 AM EDT
Filing Type: 8-K
Importance Score:
9
APTOF
Feb 23, 2026, 9:36 PM EST
Filing Type: 8-K
Importance Score:
8
APTOF
Feb 23, 2026, 8:26 PM EST
Filing Type: SC 13E3/A
Importance Score:
8
APTOF
Feb 23, 2026, 8:14 PM EST
Filing Type: DEFM14A
Importance Score:
8
APTOF
Feb 17, 2026, 6:13 AM EST
Filing Type: SC 13E3/A
Importance Score:
9
APTOF
Feb 17, 2026, 6:06 AM EST
Filing Type: PRER14A
Importance Score:
9
APTOF
Feb 09, 2026, 6:15 AM EST
Filing Type: SC 13E3/A
Importance Score:
9
APTOF
Jan 14, 2026, 9:26 PM EST
Filing Type: SC 13E3
Importance Score:
10
APTOF
Jan 14, 2026, 9:23 PM EST
Filing Type: PRER14A
Importance Score:
9